Recruiting ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC NCT06816992 Conditions EGFR Exon 20 Insertion Mutations, EGFR-mutated NSCLC, NSCLC, +1 more Locations NYU Langone Health — New York, United States Virginia Cancer Specialists — Fairfax, Virginia, United States Peter MacCallum Cancer Centre — Melbourne, Victoria, Australia The Princess Margaret Hospital — Toronto, Ontario, Canada View Trial Details
